(0.06%) 5 209.75 points
(0.21%) 39 077 points
(-0.12%) 18 175 points
(-0.18%) $78.34
(-0.36%) $2.19
(-0.39%) $2 322.00
(-0.63%) $27.44
(-0.24%) $962.55
(0.08%) $0.929
(0.37%) $10.86
(0.22%) $0.798
(-0.30%) $91.07
-1.85% $ 2.65
Live Chart Being Loaded With Signals
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection...
Stats | |
---|---|
Volumen de hoy | 6 761.00 |
Volumen promedio | 52 260.00 |
Capitalización de mercado | 47.67M |
EPS | $0 ( 2024-03-31 ) |
Próxima fecha de ganancias | ( $0 ) 2024-06-27 |
Last Dividend | $0.0750 ( 2014-01-31 ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.46 |
ATR14 | $0.0770 (2.93%) |
XORTX Therapeutics Inc. Correlación
10 Correlaciones Más Positivas | |
---|---|
VTYX | 0.922 |
ALXO | 0.895 |
RCM | 0.893 |
JRJC | 0.878 |
FEMY | 0.877 |
CTMX | 0.876 |
QRTEA | 0.875 |
GNTY | 0.873 |
GOEV | 0.872 |
NAKD | 0.87 |
10 Correlaciones Más Negativas | |
---|---|
IDCC | -0.895 |
OTEX | -0.892 |
VBOCU | -0.89 |
BLBD | -0.888 |
MPRA | -0.887 |
OVLY | -0.887 |
NVCN | -0.887 |
GPACU | -0.886 |
OVID | -0.886 |
GRBK | -0.885 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
XORTX Therapeutics Inc. Finanzas
Annual | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-0.520 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-0.520 |
Financial Reports:
No articles found.
XORTX Therapeutics Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2011-08-10 |
Last Dividend | $0.0750 | 2014-01-31 |
Next Dividend | $0 | N/A |
Payout Date | 2014-02-17 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $0.795 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.61 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.171 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.972 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.44 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 9.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 9.15 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00429 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -5.22 | 2.00 | -1.741 | -3.48 | [0 - 30] |
freeCashFlowPerShareTTM | -5.25 | 2.00 | -2.63 | -5.25 | [0 - 20] |
debtEquityRatioTTM | 0.00468 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -366.22 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.285 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.681 | 1.000 | -0.170 | 0 | [1 - 100] |
returnOnEquityTTM | -0.972 | 2.50 | -7.65 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -5.25 | 2.00 | -1.751 | -5.25 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -5.22 | 2.00 | -1.741 | -3.48 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0783 | 1.500 | -2.81 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -2.39 |
XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico